938261-59-7Relevant academic research and scientific papers
INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
-
Paragraph 00286, (2018/09/11)
Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.
Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents
Sun, Wen-Xue,Ji, Ya-Jing,Wan, Yun,Han, Hong-Wei,Lin, Hong-Yan,Lu, Gui-Hua,Qi, Jin-Liang,Wang, Xiao-Ming,Yang, Yong-Hua
, p. 4066 - 4074 (2017/08/22)
In this paper, a series of podophyllotoxin piperazine acetate ester derivatives were synthesized and investigated due to their antiproliferation activity on different human cancer cell lines. Among the congeners, C5 manifested prominent cytotoxicity towar
Synthesis, crystal structures, molecular docking, and urease inhibitory activity of transition metal complexes with 2-[4-(4-fluorophenyl)piperazin-1-yl]acetic acid
Chen, Zhi-Jian,Xu, Chun-Na,Zhu, Jin-Long,Yang, Dan-Dan,Zhao, Shan-Shan,Chen, Ya-Nan,Qian, Shao-Song
, p. 165 - 172 (2016/03/19)
Two novel mononuclear complexes, [Cu(L)2(H2O)] · 2H2O (1) and [Ni(L)2(H2O)2] (2) (HL = 2-[4-(4-fluorophenyl)piperazin-1-yl]acetic acid) were synthesized and structurally determined by singl
Arylpiperazines as fatty acid transport protein 1 (FATP1) inhibitors with improved potency and pharmacokinetic properties
Matsufuji, Tetsuyoshi,Ikeda, Mika,Naito, Asuka,Hirouchi, Masakazu,Kanda, Shoichi,Izumi, Masanori,Harada, Jun,Shinozuka, Tsuyoshi
, p. 2560 - 2565 (2013/07/04)
The discovery and optimization of a novel series of FATP1 inhibitors are described. Through the derivatization process, arylpiperazine derivatives 5k and 12a were identified as possessing potent in vitro activity against human and mouse FATP1s as well as
